Next Century Growth Investors LLC Has $2.80 Million Stake in SiBone $SIBN

Next Century Growth Investors LLC raised its position in SiBone (NASDAQ:SIBN) by 508.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 141,998 shares of the company’s stock after purchasing an additional 118,657 shares during the quarter. Next Century Growth Investors LLC owned 0.33% of SiBone worth $2,800,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone in the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. State of Wyoming bought a new position in shares of SiBone in the 2nd quarter valued at about $55,000. Canada Pension Plan Investment Board bought a new position in shares of SiBone in the 2nd quarter valued at about $68,000. Finally, Larson Financial Group LLC grew its holdings in shares of SiBone by 42.3% in the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after acquiring an additional 1,061 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Stock Performance

Shares of NASDAQ:SIBN opened at $15.42 on Monday. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The company has a market capitalization of $683.88 million, a P/E ratio of -39.54 and a beta of 0.70. The company has a 50-day simple moving average of $13.94 and a 200 day simple moving average of $15.81. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The business had revenue of $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. Sell-side analysts forecast that SiBone will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Truist Financial restated a “buy” rating and issued a $18.00 price objective (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.00.

Insiders Place Their Bets

In related news, Director Jeffrey W. Dunn sold 3,575 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $15.25, for a total value of $54,518.75. Following the completion of the sale, the director directly owned 16,057 shares in the company, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Anshul Maheshwari sold 3,318 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $12.87, for a total transaction of $42,702.66. Following the completion of the sale, the chief financial officer owned 263,148 shares of the company’s stock, valued at $3,386,714.76. This trade represents a 1.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,327 shares of company stock worth $520,834 in the last three months. Insiders own 3.90% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.